The safety of the combination therapy of recombinant factor VIIa and plasma-derived factor VIIa and factor X for refractory hemorrhage in acquired hemophilia A
aDepartment of Hematology, Graduate School of Medicine, Osaka Metropolitan University, Osaka
bDepartment of Laboratory Medicine, Tokyo Medical University, Tokyo, Japan
Correspondence to Yasuhiro Nakashima, MD, PhD, Department of Hematology, Graduate School of Medicine, Osaka Metropolitan University, 1-4-3 Asahi-machi, Abeno, Osaka 545-8585, Japan Tel: +81 6 6645 3881; fax: +81 6 6645 3880; e-mail: [email protected]
Received 3 November, 2022
Revised 26 June, 2023
Accepted 6 July, 2023
留言 (0)